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Abstract
Background: Apolipoprotein E (apoE) is a major protein of the lipoprotein transport system that plays important roles in
lipid homeostasis and protection from atherosclerosis. ApoE is characterized by structural plasticity and thermodynamic
instability and can undergo significant structural rearrangements as part of its biological function. Mutations in the 136–150
region of the N-terminal domain of apoE, reduce its low density lipoprotein (LDL) receptor binding capacity and have been
linked with lipoprotein disorders, such as type III hyperlipoproteinemia (HLP) in humans. However, the LDL-receptor binding
defects for these apoE variants do not correlate well with the severity of dyslipidemia, indicating that these variants may
carry additional properties that contribute to their pathogenic potential.
Methodology/Principal Findings: In this study we examined whether three type III HLP predisposing apoE3 variants,
namely R136S, R145C and K146E affect the biophysical properties of the protein. Circular dichroism (CD) spectroscopy
revealed that these mutations do not significantly alter the secondary structure of the protein. Thermal and chemical
unfolding analysis revealed small thermodynamic alterations in each variant compared to wild-type apoE3, as well as effects
in the reversibility of the unfolding transition. All variants were able to remodel multillamelar 1,2-Dimyristoyl-sn-glycero-3-
phosphocholine (DMPC) vesicles, but R136S and R145C had reduced kinetics. Dynamic light scattering analysis indicated
that the variant R136S exists in a higher-order oligomerization state in solution. Finally, 1-anilinonaphthalene-8-sulfonic acid
(ANS) binding suggested that the variant R145C exposes a larger amount of hydrophobic surface to the solvent.
Conclusions/Significance: Overall, our findings suggest that single amino acid changes in the functionally important region
136–150 of apoE3 can affect the molecule’s stability and conformation in solution and may underlie functional
consequences. However, the magnitude and the non-concerted nature of these changes, make it unlikely that they
constitute a distinct unifying mechanism leading to type III HLP pathogenesis.
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Introduction
Apolipoprotein E (apoE) is a major protein of the lipoprotein
transport system that plays critical role in the protection from
atherosclerosis and dyslipidemia [1]. ApoE mediates the hepatic
clearance of lipoprotein remnants from circulation serving as a
ligand for the low-density lipoprotein (LDL) receptor [2].
Additionally, apoE interacts with other members of the LDL
receptor family and cell-surface heparan sulfate proteoglycans
(HSPGs)[3,4]. ApoE is also involved in cholesterol efflux processes
[5,6] and thus may contribute to cell and tissue cholesterol
homeostasis [7,8]. ApoE contains 299 residues and has three
common isoforms (apoE2, apoE3, apoE4) in the general
population, each differing in the amino acid positions 112 and
158 [9,10]. ApoE3, the most common form, contains cysteine at
position 112 and arginine at position 158, whereas apoE2 has two
cysteine residues and apoE4 has two arginine residues at these two
positions. ApoE4 is a major genetic risk factor for late-onset
Alzheimer’s disease [11,12].
In the lipid-free state apoE is folded into two independent
structural domains. Digestion with thrombin produces a 22-kDa
N-terminal fragment (residues 1 to 191) and a 10-kDa C-terminal
fragment (residues 216 to 299) [13,14]. X-ray crystallography
studies showed that the N-terminal domain is folded into a four-
helix bundle of amphipathic a-helices spanning residues 24-164
that are stabilized by hydrophobic interactions and salt bridges
[15,16,17]. The C-terminal domain is highly a-helical, as
determined by computer modeling and circular dichroism
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apoE4, the N- and C-terminal domains interact differently than in
the other isoforms, since Arg-112 results in the orientation of the
Arg-61 side chain in the N-terminal domain of apoE4 away from
the four-helix bundle. This orientation allows Arg-61 to form a salt
bridge with Glu-255 in the C-terminal domain [16,20]. In apoE3
and apoE2 Arg-61 and Glu-255 do not interact.
Homozygosity for the apoE2 isoform, which has defective in vitro
binding capacity to the LDL receptor, is present in the vast
majority of subjects with type III hyperlipoproteinemia (HLP)
[21,22]. This lipid disorder is characterized by xanthomas,
elevated plasma cholesterol and triglyceride levels, and is
associated with premature atherosclerosis in humans and exper-
imental animal models of the disease [23,24,25]. Besides apoE2,
which is associated with a recessive form of type III HLP, a variety
of rare naturally-occurring apoE mutations have also been
described that are associated with a dominant mode of inheritance
of type III HLP which is expressed at an early age [22]. Most of
these apoE mutations are between residues 136 to 150 [22,26].
Specifically, heterozygosity for the apoE variant apoE3[R136S]
(previously designated apoE2 Christchurch) with the apoE2 allele
results in type III HLP [27]. In vitro studies showed that lipid-
bound apoE3[R136S] displays a reduction of 60% in LDL
receptor binding capacity as compared to wild-type apoE3 [28].
Additionally, it has been shown that homozygosity for
apoE3[R136S] and heterozygocity for apoE3[R136S] with all
apoE alleles result also in type III HLP, but the penetrance of the
disease is incomplete [29]. Homozygosity and heterozygocity for
the apoE variant apoE3[R145C] has also been associated with
severe type III HLP [30,31]. Binding studies showed that lipid-
bound apoE3[R145C] has 55% reduced LDL receptor binding
capacity compared to apoE3 and the 22-kDa domain of lipid-
bound apoE3[R145C] has 48% reduced HSPG binding capacity
compared to apoE3-22kDa [30,32]. Finally, heterozygosity for the
apoE variant apoE3[K146E] with the apoE3 allele resulted in a
dominant expression of type III HLP [33,34,35]. Lipid-bound
apoE3[K146E] had less than 10% binding capacity to the LDL
receptor and HSPG compared with apoE3 [34,35,36].
Interestingly, receptor binding defects for these apoE variants
do not correlate well with the severity of dyslipidemia, which can
be influenced by other secondary factors [28,37,38]. Furthermore,
the degree of penetrance varies depending on the mutation [22].
Factors may affect the severity of dyslipidemia in patients carrying
these mutations include the natural apoE polymorphism which
affects the distribution of apoE to different lipoprotein classes [39],
interaction of apoE with HSPGs [40] or additional genetic,
hormonal, or environmental factors, such as obesity, hypothy-
roidism, estrogen status, or diabetes [41].
Several studies have suggested that the structural and biophysical
properties of apoE can dictate the function of the protein and have
provided insight into the mechanisms by which apoE is involved in
cardiovascular and neurological diseases [42,43,44,45,46,47,48,49].
In the current study we tested whether three naturally-occurring
point variants of apoE3 linked with the development of type III
HLP affect the thermodynamic stability of the molecule. The
R145C, K146E and R136S mutations are all located within helix 4
of the N-terminal four-helix bundle of the protein (Figure 1) and
encode for non-conservative amino acid substitutions. We therefore
hypothesized that such drastic residue changes may affect protein
stability and conformation. Furthermore, we hypothesized that
shared changes in the biophysical properties of these variants may
support disease phenotypes. To test this hypothesis, we employed
circular dichroism (CD) spectrometry to compare the secondary
structure and thermal denaturation profiles of the variants
compared to the wild-type apoE3. We used fluorescence spectros-
copy to analyze their chemical denaturation profiles and 1-
anilinonaphthalene-8-sulfonic acid (ANS) hydrophobic probe
binding to quantitate solvent-exposed hydrophobic surfaces.
Furthermore, we used dynamic light scattering to assess the solution
oligomerization state of the apoE3 variants. Finally, we measured
the kinetics of remodeling of multilamellar 1,2-Dimyristoyl-sn-
glycero-3-phosphocholine (DMPC) vesicles by each variant.
Overall, our data point to changes in some of the biophysical
parameters of each variant compared to the wild-type form
suggesting that even single-amino acid changes in this region of
the protein can influence the stability and conformation of apoE3.
These changes however are not concerted amongst the three
mutations, suggesting that the alterations in the biophysical
properties of these apoE3 variants do not constitute a single
unifying mechanism underlying their pathogenic potential.
Materials and Methods
Site-directed mutagenesis and adenovirus construction
ApoE3 variants were constructed using the QuikChange-XL
(Stratagene) side-directed mutagenesis kit, using as a template the
vector pGEM7-apoE3 containing exons II, III and IV of human
Figure 1. Top, Cartoon representation of the N-terminal
structure of human apoE3 (PDB code: 1LPE) indicating the
location of the mutations; protein is depicted in side and top
view. Bottom, SDS-PAGE analysis of the recombinant apoE3 variants
and wild-type protein. Molecular mass marker bands are indicated.
Images were prepared using PyMol 1.3 (www.pymol.org).
doi:10.1371/journal.pone.0027037.g001
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R136S the following sets of primers were used: R136S-f (59-GAG
GAG CTG CGG GTG AGC CTC GCC TCC CAC CTG-39)
and R136S-r (59-CAG GTG GGA GGC GAG GCT CAC CCG
CAG CTC CTC-39) for the first variant, R145C-f (59- CAC CTG
CGC AAG CTG TGT AAG CGG CTC CTC CGC-39) and
R145-r (59-GCG GAG GAG CCG CTT ACA CAG CTT GCG
CAG GTG-39) for the second variant, K146E-f (59-CTG CGC
AAG CTG CGT GAG CGG CTC CTC CGC GAT-39) and
K146E-r (59-ATC GCG GAG GAG CCG CTC ACG CAG
CTT GCG CAG-39) for the third variant. Successful mutagenesis
was confirmed by sequencing the template vector. Recombinant
adenoviruses were constructed as previously described [50] using
the Ad-Easy-1 system [51]. Correct clones were propagated in
RecA DH5a cells [51]. The recombinant adenoviral vectors were
linearized with PacI and used to infect 911 cells [52]. Human
embryonic kidney 293 cell cultures (ATCC number CRL-1573)
were used for large-scale amplification of the viruses [51].
Protein expression
Human astrocytoma HTB13 cells (ATCC number HTB-13,
designation SW 1783) grown in roller bottles were infected with the
appropriate recombinant adenoviruses with a multiplicity of
infection of 20 pfu/cell. The medium (Leibovitz L-15 containing
1% v/v penicillin and streptomycin and 2% v/v heat-inactivated
horse serum) was discarded 24 hours post-infection and the cells in
the roller bottles were rinsed with Dulbecco’s phosphate-buffered
saline (DPBS). The DPBS was discarded and Leibovitz L-15
medium containing 1% v/v penicillin and streptomycin was added.
The medium was harvested 24 hours later and the harvest was
repeated at24-hourintervalsfor4-6days.Thecollectedmediawere
centrifuged and filtered through 0.2 mm sterile filters and were
stored at -80uC. The amount of the expressed wild-type and variant
apoE3 forms was estimated by SDS-PAGE. The medium
containing the recombinant protein was lyophilized to reduce total
volumeto,200 mland thenextensivelydialyzed against25 mMof
ammoniumbicarbonate. The dialyzed medium was lyophilized and
the dried recombinant protein stored at 280uC.
Protein purification
Recombinant wild-type and variant apoE3 forms were purified
by a lipidation/de-lipidation protocol involving formation of
proteoliposomes, density gradient ultracentrifugation of proteoli-
posomes to isolate pure apoE3 and then delipidation of purified
apoE3 followed by chemical refolding. The procedure is described
bellow for delipidating one mg of recombinant apoE3:
9.5 mg of b-oleoyl-c-palmitoyl-L-a-phosphatidylcholine (POPC,
Avanti Polar Lipids) and 0.47 mg of cholesterol (Sigma) / mg of
apoE3 to be delipidated were mixed and dissolved in ,10 ml of
chloroform:methanol solution (2:1 v/v). The solution was dried
under gas nitrogen. A volume of 0.42 ml of saltbuffer (10 mM Tris-
HCl, 150 mM NaCl, 0.01% EDTA, pH8.0) per mg of apoE3 was
added in the flask with the dried cholesterol and phospholipids. The
flask was flashed with nitrogen gas, tapped and stirred vigorously for
1h ,a t4 uC. Lyophilized recombinant apoE3 was dissolved in salt
buffer at 2 mg/ml and was added to the lipid emulsion. The
solution was further stirred vigorously for 1 h, at 4uC. Finally,
150 ml/mg apoE3 of a 30 ml/ml sodium cholate stock was added to
the solution under stirring, and the mixture was stirred at 4uC for
one more hour. The solution of proteoliposomes was then dialyzed
3 times against 10 mM Tris-HCl, 150 mM NaCl, 0.01% EDTA,
pH 8.0 at 4 uC.
The proteoliposomes’ solution was adjusted to a density of
1.21 g/ml by the addition of KBr. A volume of 13.2 ml of the
proteoliposome solution (d=1.21 g/ml) was transferred to the
bottom of 40 ml Beckman tubes and overlaid by 6.6 ml of KBr
solution of d=1.063 g/ml, followed by 6.6 ml of KBr of
d=1.019 g/ml and 13.2 ml of DPBS to the top of the tube.
The tubes were transferred to a SW28 rotor and centrifuged at
28000 rpm for 22 hours at 4uC. Following centrifugation, 2 ml
fractions were collected from the top. The fractions were dialyzed
extensively against ddH2O. An aliquot of 20 ml of each fraction
were analyzed by SDS-PAGE. The fractions that contained pure
apoE3 were pooled and stored at 4uC.
To delipidate the apoE3 containing fractions, aliquots of 3 ml
were transferred in sterile siliconized 30 ml Corex
TM tubes and
then diluted by the addition of 3 ml ammonium bicarbonate
buffer (50 mM final concentration). A volume of 23.1 ml of fresh
chloroform:methanol (2:1 v/v) solution was added to each tube.
The solution was vortexed vigorously, incubated on ice for at least
3 h and the tubes were centrifuged at 8000 rpm using a Beckman
JA-20 rotor at 4uC for 30 min to separate the two phases. During
this procedure an amorphous precipitate formed between the two
phases corresponding to precipitated apoE. The two phases as well
as the intermediate precipitate were carefully separated. The top
aqueous phase containing apoE was dried under nitrogen gas to
remove any residual chloroform and methanol. The bottom
organic phase was submitted to the same extraction procedure at
least three more times until no more phosphorus could be detected
in the aqueous phase as determined by the Bartlett method [53].
The pooled inter-phase precipitate contained pure delipidated
apoE3 that had precipitated during the extraction procedure and
was refolded as described below. Purified proteins were dried
completely and stored in lyophilized form at 280uC.
Before all analyses, lyophilized stocks of wild-type or apoE3
variants were subjected to a refolding protocol as previouslydescribed
[43]. Brieflythe protein powder was dissolved at a final concentration
of 0.2 mg/ml in 6 M guanidine hydrochloride in DPBS containing
1 mM DTT. The solution was incubated for 1 h at room
temperature and then dialyzed 3 times against DPBS pH 7.4. After
dialysis samples were centrifuged at 10000 g for 20 min to remove
any precipitated protein. The refolded proteins were quantitated by
measuring their absorbance at 280 nm using an extinction coefficient
of 1.3 mg
21 mL cm
21. The proteins were kept at low concentrations
(,0.1 mg/ml) on ice to avoid aggregation. All analyses were
performed on freshly refolded protein.
Circular Dichroism Spectroscopy
Far-UV CD spectra were recorded from 190 to 260 nm at 25uC
using a Jasco-715 spectropolarimeter. The cuvette chamber was
thermostated using a Jasco PTC-348 WI Peltier temperature
controller. Protein samples were at 0.1 mg/ml concentration in
DPBS (pH 7.4) containing 1 mM DTT (Applichem). A quartz
cuvette with an optical path length of 1 mm was used. Spectra
were acquired at 1 nm bandwidth, 8 sec response time, 0.2 nm
step size and 50 nm/min scan speed. Each spectrum was
calculated as the average of 5 accumulations. The results were
corrected by subtracting the buffer baseline.
Helical content was calculated using the molecular ellipticity at
208 and 222 nm as described by Greenfield et al. [54] using the
equations:
%a-helix~ H ½  222z3000

= 36000z3000 ðÞ |100
Helical content was also calculated using the DICHROWEB
server [55]. The CDSSR method was selected for calculations
because it yielded the lowest NRMSD value [56,57].
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ellipticity at 222 nm was monitored while varying the temperature
in the range 20–80uC at a rate of 1uC /min. The thermal
denaturation curve was fitted to a Boltzman sigmoidal model
curve using the Graphpad Prism
TM software. The relative
enthalpy change was calculated as described previously [58].
The cooperativity index, n, was calculated as previously described
[42] (using the Hill equation n=(log 81)/log(T0.9/T0.1), where T0.9
and T0.1 are the temperatures where the unfolding transition has
reached a fractional completion of 0.9 and 0.1. For thermal
unfolding reversibility measurements, the thermally denatured
sample was cooled down to 20uC at a rate of 1uC /min and then
re-heated to 80uC while recording the molar ellipticity at 222 nm.
Chemical denaturation experiments
To record the chemical denaturation profile of apoE3 0.04 mg/
mL of freshly refolded protein were added in a 4 mL quartz
fluorimeter cuvette in a jacketed holder at 25uC, and the intrinsic
tryptophan protein fluorescence was measured at 340 nm after
excitation at 295 nm. Small amounts of an 8.0 M guanidine
hydrochloride (Applichem) solution in DPBS were gradually
added in the cuvette. The contents were mixed by repeated
pipetting for 5 sec, incubated in the dark for 2 min and then the
fluorescence signal of the sample was measured. The experimental
data were fitted to a three-state denaturation model as described
by Ekblad et al. [59] using the following equation:
y~ TNzA1 TIzTUA2 ðÞ ðÞ = 1zA1 1zA2 ðÞ ðÞ ;
where y is the fluorescence signal, TN,T I, TU is the fluorescence
signal for the native, intermediate and unfolded state of the protein
respectively and A1 and A2 are:
A1~exp mni x{xni50 ðÞ ðÞ =RT ðÞ ;
A2~exp miu   x{xiu50 ðÞ ðÞ =RT ðÞ ;
where x is the denaturant concentration, R is the universal gas
constant (0.001986 kcal K
21 mol
21), T is the temperature of the
experiment (298 K), xni and xiu are the mid-transition points for the
transition from the native to the intermediate state and from the
intermediate to the unfolded state respectively. Finally, mni and miu
correspond to the slope of the mid-transition points from the native
to the intermediate state and from the intermediate to the unfolded
state respectively. The relative change in Gibbs-free energy during
the chemical denaturation was calculated as follows [59]:
DG1~mnixni
DG2~miuxiu
DGtotal~DG1zDG2(kcal=mol)
ANS Fluorescence
1,8 ANS (1-anilinonaphthalene-8-sulfonic acid, Sigma-Aldrich)
was dissolved into dimethylsulfoxide (DMSO) to a final concen-
tration of 50 mM (ANS stock solution) and stored at 220uC.
Freshly refolded wild-type and apoE3 variants in 1x DPBS
pH 7.4, 0.1 mM DTT at 0.04 mg/ml were inserted into a 4 mL
quartz fluorimeter cuvette (Hellma, Germany). Fluorescence
measurements were preformed in a Quantamaster 4 fluorescence
spectrometer (Photon Technology International, New Jersey). The
scan rate was 1 nm/s with excitation at 395 nm and emission
Figure 2. Circular dichroism spectra of wild-type apoE3 and
variants (wild-type in black, R145C in blue, K146E in red and
R136S in green). Spectra shown are the average of three separate
measurements on different days with different protein batches. Inset:
Helical content of WT apoE3 and variants calculated using the molar
ellipticity at 222 nm as described in the materials and methods section.
Error bars represent standard deviation based on three independent
measurements.
doi:10.1371/journal.pone.0027037.g002
Table 1. Secondary structure content for apoE3 and variants calculated from Circular Dichroism spectroscopy experiments.
apoE3 % a-helix222 nm
1 CDSSTR
2
% Helix % Strand % Turns % Unordered NRMSD
3
WT 58.763.2 62 15 10 13 0.004
R145C 56.861.2 59 16 11 14 0.005
K146E 59.762.2 61 16 10 12 0.004
R136S 59.464.9 60 16 11 14 0.004
1Values are means 6 SD from three to four experiments.
2prediction is averaged over sets 4,7 and SP175.
3parameter refers to quality of fit of modeled spectra to actual spectra, see reference [57].
doi:10.1371/journal.pone.0027037.t001
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protein fluorescence, 7.5 mL of ANS stock solution were added in
the cuvette and mixed so that the final ANS concentration was
250 mM. A control ANS spectrum in the absence of protein was
also recorded to allow the calculation of ANS fluorescence
enhancement in the presence of apoE3.
DMPC remodeling kinetics
Dimyristoyl-L-a-phosphatidylcholine (DMPC) remodeling as-
says were performed as described previously [60,61] with the
following modifications: DMPC concentration was 97 mg/ml and
apoE3 concentration was 43 mg/ml. The reaction was performed
in DPBS with 3.5% KBr (w/v), 0.1 mM DTT, 0.1 M guanidine
hydrochloride (GndHCl), 0.1 mM EDTA. Reaction kinetics were
followed by the change in absorbance at 325 nm using a Perkin-
Elmer (USA) Lambda 35 UV/VIS spectrophotometer. The
cuvette (1 cm pathlength) was thermostated at 2460.1uC using
the Perkin-Elmer PCB 1500 Peltier temperature controller. The
contents were mixed by repeated pipetting for 3 sec every 2 min.
Experimental data were fitted to a two-phase exponential decay
model using Graphpad Prism
TM.
Dynamic Light Scattering Analysis
Dynamic light scattering (DLS) experiments were recorded on a
Zetasizer nano series instrument (Malvern Instruments Ltd, UK)
at 25uC. ApoE3 samples were at 0.1 mg/ml in DPBS.
Statistical analysis
Equation fitting was performed by Graphpad Prism
TM. To test
the reproducibility of the results we applied a paired student t-test
to experimental data collected from separately refolded protein
batches. Each experimental set was comprised by both the wild-
type (WT) protein and all three variants. For thermal and chemical
denaturation measurements as well as ANS binding, statistical
analysis was performed using experimental data collected on
separate days. For DMPC remodeling measurements all experi-
ments were performed on the same day to minimize variability
from the preparation of the DMPC vesicles.
Results
Protein expression and purification
All four proteins (wild-type apoE3 and variants R145C, K146E
and R136S) were expressed by HTB13 cells after infection with
recombinant adenovirus carrying the apoE3 gene with the desired
mutation and purified to homogeneity by a lipidation/delipidation
protocol as described in the materials and methods section. The
location of the 3 mutations on the crystallographic structure of the
N-terminal fragment of apoE3 is shown in Figure 1. SDS-PAGE
analysis indicated that all four recombinant proteins migrated with
identical profiles and were more than 98% pure (Figure 1). The
presence of a higher MW band corresponds to sialylated forms of
Figure 3. Thermal denaturation profiles of wild-type apoE3
and apoE3 variants. Each apoE3 variant (black dots) is presented in
comparison with the wild-type protein (gray dots).
doi:10.1371/journal.pone.0027037.g003
Table 2. Parameters calculated for the thermal unfolding of
apoE3 and variants.
apoE3 Tm (6C) n
1
apparent DG
(kcal/mol)
1
WT 53.660.2 7.760.2 27.960.1
R145C 53.460.3 6.9±0.4
*** 21.3±1.4
****
K146E 55.7±0.1
* 7.960.2 27.361.1
R136S 51.9±0.4
** 7.660.6 27.460.8
Values are means 6 SD from three to four experiments.
*p=0.002, ** p=0.004, *** p=0.015, **** p=0.007.
1parameters calculated assuming a reversible two-state model.
doi:10.1371/journal.pone.0027037.t002
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deglycosylating the protein using Clostridium perfringens Neur-
aminidase (not shown).
Secondary structure of apoE3 variants
Since all three mutations are located in the helical region of
apoE3 (Figure 1A) we first investigated whether they affect the
secondary structure of that region. We measured the circular
dichroism signal of each apoE3 variant in the far UV region and
compared it to the signal of the wild-type apoE3 protein. The
overall shape of the CD spectrum in the region 190–260 nm was
essentially identical between the variants and wild-type apoE3
indicating that the mutations did not affect the secondary structure
of the protein (Figure 2). All three variants were estimated to carry
similar amounts of helical content (Table 1 and Figure 2, inset).
Although small differences were evident, these changes were not
found to be statistically significant over the experimental variation
between different protein preparations measured on different days.
Overall, we conclude that the mutations R145C, K146E and
R136S do not significantly affect the secondary structure of apoE3.
Thermal denaturation measurements
To test whether the apoE3 variants have altered thermody-
namic stability, we followed the molecular ellipticity at 222 nm
while the protein was gradually unfolded by increasing the
temperature of the sample from 20 to 80uC. All three variants as
well as wild-type apoE3 underwent a single, moderately
cooperative transition to an unfolded state that contained
significantly less helical content (Figure 3). The data were fit to a
Boltzmann sigmoidal equation describing a transition between two
states. Although the thermal denaturation of apoE3 is not a fully
reversible process due to protein aggregation, such analysis has
been used before as a method of comparing changes between
apoE3 variants, primarily because the irreversible changes are
relatively slow compared to the heat unfolding [64]. We therefore
calculated the thermal midpoint of the transition, Tm, the
apparent cooperativity coefficient n, and the apparent enthalpy
change of the transition DH (Table 2). ApoE3-K146E was found
to undergo thermal denaturation at about 2uC over the wild-type
protein whereas apoE3-R136S had a Tm at about 2uC lower
compared to the wild-type protein. Although these changes are
relatively small, they were found to be statistically significant
(p,0.005) and suggest subtle changes in the distribution of
conformations between variants. ApoE3-R145C presented the
most prominent changes in thermal denaturation profile. Al-
though the Tm of apoE3-R145C was identical to that of the wild-
type protein, the shape of the transition was less steep as evident
from the change in the cooperativity coefficient n (Figure 3 and
Table 2). As a result, the apparent DH of the transition for apoE3-
R145C was decreased by almost 7 kcal/mol compared to the
wild-type protein and the other two variants indicating that this
single amino acid change can have significant impact on the
thermal stability of apoE3 (Table 2).
Consecutive heating and cooling of apoE3 samples was utilized
to gauge the reversibility of the thermal unfolding. It has been
demonstrated before that apoE3 thermal unfolding is only
partially reversible due to the slow aggregation of the protein
[64]. To investigate whether the variants share this property, we
conducted consecutive heating, cooling and re-heating on each
apoE3 sample (Figure 4). Wild-type apoE3 showed a mostly non-
reversible transition with a close to 60% signal recovery upon
cooling. The second unfolding transition however, did demon-
strate similar sigmoidal shape and Tm to the first indicating that
part of the protein ensemble was able to undergo a reversible
transition. ApoE3 variant R145C demonstrated a similar pattern
with minor differences in the amount of CD signal recovery upon
refolding. Surprisingly, apoE3 variants R136S and K146E
demonstrated a predominantly reversible transition, recovering
about 95-99% of the signal upon cooling. This finding suggests
that these variants may have different competing kinetics between
refolding and thermally induced aggregation, indicative of changes
in the conformational plasticity of the protein.
Chemical denaturation measurements
To further investigate possible changes in the thermodynamic
stability of apoE3 due to the presence of mutations R145C,
K146E and R136S we studied the chemical denaturation profile of
the apoE3 variants (Figure 5). The tryptophan fluorescence signal
of each protein variant was followed as a function of increasing
concentration of the chaotrope guanidine hydrochloride. All three
variants exhibited similar shape curves as wild-type apoE3 with a
characteristic shallow plateau near the midpoint of the denatur-
ation, indicative of a transition intermediate state as described
before [43]. To analyze the thermodynamics of these transitions
we fitted the experimental data to a 3-state denaturation model
that allowed us to calculate the apparent change of the free Gibbs
Figure 4. Reversibility of the thermal denaturation of WT apoE3 and variants. ApoE3 was thermally unfolded while following the CD signal
at 222 nm (red trace). After reaching 80uC, the protein was gradually refolded by cooling the sample chamber down to 20uC (blue trace). The protein
sample was then thermally unfolded again (green trace).
doi:10.1371/journal.pone.0027037.g004
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results of the fit are shown in Table 3. ApoE3-R145C and apoE3-
R136S had a DG of 4.660.2 and 4.860.2 kcal/mol respectively,
values that did not statistically differ from the value calculated for
the wild-type protein (4.460.2 kcal/mol). ApoE3-K146E however
had a DG of 6.060.3 kcal/mol, a value that was about 1.6 kcal/
mol higher than the wild-type protein (p=0.08) indicating
stabilization of this variant compared to the wild-type protein.
This stabilization was found to be primarily due to the stabilization
of the second unfolding transition of apoE3 variant (Table 3) that
corresponds to the unfolding of the N-terminal domain where the
K146E mutation is located [13,44,65].
ANS binding measurements
Binding of ANS onto apoE has been previously used to probe
the hydrophobic binding properties of the molecule and as a
measure of possible conformational rearrangements [43]. To
examine whether the mutations under study here affect the solvent
exposure of hydrophobic regions of the protein we measured ANS
fluorescence in the presence of wild-type apoE3 and its variant
forms (Figure 6). Binding of ANS to apoE3 resulted in a marked
increase of its fluorescence signal accompanied by a blue-shift
consistent with ANS binding to hydrophobic sites on the protein.
ApoE3 variants R136S and K146E did not show any statistically
significant change in ANS fluorescence compared to wild-type
apoE3 (Figure 6 and Table 3). However, apoE3 variant R145C
did demonstrate enhanced ANS fluorescence over wild-type
apoE3. These measurements are consistent with the nature of
the mutated amino acid, since we observed increased ANS
fluorescence only for the apoE3 variant in which a hydrophilic
residue (Arg) is substituted for a more hydrophobic residue (Cys). It
is notable however, that a single amino acid substitution can lead
to a sufficiently enhanced, solvent-accessible, hydrophobic surface
that can affect ANS binding.
DMPC remodeling kinetics
ApoE interacts with lipids by a complex mechanism that
includes significant conformational changes including the partial
unfolding of its N-terminal domain [47,48,60,61,66,67]. To test
whether the mutations studied here can affect this process we
measured the kinetics of DMPC vesicles remodeling in the
presence of the apoE3 variants (Figure 7 and Table 4). All three
variants were efficient in clearing DMPC vesicles with relatively
slow kinetics, similarly to the WT apoE3. The data were fit to a bi-
phasic exponential decay equation as described in Materials and
Methods, allowing the accurate determination of the slow and fast
component half-lives (Table 4). This analysis indicated small, but
statistically significant, differences in the slow component of the
decay for variants R145C and R136S. These changes may be
related to the kinetics of the N-terminal four-helix bundle opening
upon interactions with phospholipids.
Dynamic Light Scattering Measurements
ApoE has been shown to exist in oligomeric states in solution,
ranging from dimers to octamers, but predominantly tetramers,
mediated by interactions of its C-terminal domains [14,49,64]. To
test the oligomerization state of the variants we used Dynamic Light
Scattering to determine each variant’s hydrodynamic diameter in
solution, at the concentration range typically used for biophysical
analysis (0.1 mg/ml). The particle size distribution, normalized by
intensity and volume occupancy in the ensemble is shown in
Figure 8. In all cases .99% of the scattering mass was found to
originate from species in the 10–20 nm diameter range, with ,1%
of the mass corresponding to higher-order aggregates. Both the WT
apoE3 and variant K146E demonstrated a similar distribution with
a predominant particle diameter of 10.461.7 and 10.161.7 nm
respectively (Figure 8 and Table 5). The R145C variant had a
similar hydrodynamic diameter but with a slightly larger distribu-
tion possibly indicating a tendency towards aggregation. Interest-
ingly, the R136S variant demonstrated a significantly higher
Figure 5. Chemical denaturation profiles of wild-type apoE3
and apoE3 variants. Each variant is presented in comparison with the
wild-type protein (black circles). Solid lines represent non-linear
regression fits to a three-state unfolding model as described in the
materials and methods section.
doi:10.1371/journal.pone.0027037.g005
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it exists in a higher-order oligomerization state compared to the
wild-type protein.
Discussion
The postulated multiple conformational states of apoE3 make it
challenging to unequivocally provide a structural explanation for
the observed changes in the protein’s biophysical properties. Up
until recently, direct structural information existed only for the N-
terminal segment of apoE3 that has the topology of a four-helix
bundle (pdb code, 1LPE, Figure 1). In this structure, the amino
acid positions studied here are all largely exposed to the solvent
and are thought to mediate interactions with the LDL receptor.
During the authoring of this manuscript however, a new structure
of a monomeric mutant of apoE3 was published, a structure that
provides an invaluable snapshot of the apoE3 conformational
ensemble in solution [68]. In this structure (pdb code: 2L7B) the
N-terminal segment of the protein is also folded in a four-helix
bundle (Figure 9A) with the locations of amino acids R136, R145
and K146 in similar configurations as in structure 1LPE. The C-
terminal domain is highly helical and folded around the N-
terminal domain in such a configuration to completely protect the
LDL-receptor binding region 136-150 from the solvent (Figure 9B).
As a result of this interaction, Chen et al proposed that in order for
apoE3 to interact with the LDL-receptor, it has to partially unfold
to expose this site[68]. All three amino acids under study here
participate in specific inter-domain interactions that stabilize their
charged/hydrophilic nature allowing their sequestration from the
solvent (Figure 9C). These interactions are expected to be
abrogated in the variants under study here, essentially perturbing
important domain interactions in apoE3. Changes in inter-domain
interactions can influence folding and unfolding transitions leading
to the observed effects in the biophysical behavior of the apoE3
variants. Inter-domain interactions within apoE have been
hypothesized to underlie key conformational changes related to
apoE function [44,45]. Although it is difficult to unequivocally
explain these phenomena without knowing the protein’s unfolding
and folding pathways, some interesting correlations can be
derived. For example, variant R136S is found to be prone to
Table 3. Parameters calculated from chemical denaturation and ANS binding experiments for wild-type and apoE3 variants.
apoE3
app. DG1
(kcal/mol)
app .DG2
(kcal/mol)
app. DGtotal
(kcal/mol)
mni
1
(kcal mol
-1
M
-1)
miu
1
(kcal mol
-1 M
-1)x ni
2 (M) xiu
2 (M)
ANS binding (fold
increase)
WT 1.060.2 3.460.1 4.460.2 2.660.2 1.660.1 0.3960.02 2.0960.03 3.660.5
R145C 0.960.2 3.660.2 4.660.2 2.560.2 1.660.2 0.3660.08 2.33±0.04*
4 4.2±0.4*
6
K146E 1.060.2 4.9±0.3*
1 6.0±0.3*
2 2.760.2 2.1±0.3*
3 0.3960.03 2.32±0.03*
5 3.960.4
R136S 1.260.2 3.760.1 4.860.2 2.760.2 1.760.1 0.4460.03 2.0960.03 3.960.5
Values are means 6 SD from three to four experiments.
*
1p=0.07,
*
2p=0.08,
*
3p=0.08,
*
4p=0.024,
*
5p=0.06,
*
6p=0.03
1xni and xiu are the mid-transition points for the transition from the native to the intermediate state and from the intermediate to the unfolded state respectively.
2mni and miu correspond to the slope of the mid-transition points from the native to the intermediate state and from the intermediate to the unfolded state
respectively.
doi:10.1371/journal.pone.0027037.t003
Figure 6. ANS fluorescence spectra in the presence or absence
of wild-type apoE3 and variants. Spectra are averages of three
independent experiments. Error bars indicate standard deviation based
on three independent measurements. *p=0.03.
doi:10.1371/journal.pone.0027037.g006
Figure 7. Time course of remodeling of multilamellar DMPC
vesicles by wild-type apoE3 and apoE3 variants. Absorbance at
325 nm was followed for 1 hr after addition of apoE3 to DMPC vesicles
as described in the materials and methods section. Experimental data
(closed circles) were fit to a two-phase exponential decay model (solid
lines).
doi:10.1371/journal.pone.0027037.g007
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with E231 a residue suggested to participate in the oligomerization
of apoE3 based on recent studies [69,70]. Furthermore, variant
R145C was found to expose additional hydrophobic surfaces to
the solvent and it is expected to destabilize the interaction between
amphipathic helices N1 and 4 possibly leading to partial exposure
of the intra-helix core[68]. Finally, variants K146E and R136S are
expected to perturb interactions between the N- and C-terminal
domains and are found to grossly affect the unfolding reversibility
of apoE3, a transition that would be expected to be dominated by
the ability of these two domains to interact reversibly.
Single amino acid substitutions in the N-terminal moiety of
apoE have been shown before to affect the proteins biophysical
behavior, function and role in disease pathogenesis. Specifically,
functional differences between apoE4 and apoE3 have been
attributed to altered inter-domain interactions brought about by
the polymorphism at position 112 of the N-terminal domain. This
polymorphic variation brings about alterations in the thermody-
namic properties of the molecule that may underlie functional
changes linked with disease predisposition [61,65,71,72,73,74]. It
is conceivable that the three mutations studied here influence the
thermodynamic stability and conformation of full-length apoE3 in
a similar manner. Similarly, differences in function and disease
predisposition are established between apoE3 and apoE2 although
these two variants differ only at a single amino acid at position 158
[65,72,74]. In this context, the finding that rare pathogenic
mutations in the N-terminal domain of apoE3 affect thermody-
namic stability parameters of the full-length molecule is consistent
Table 5. Parameters calculated from DLS experiments for
apoE3 variants (Figure 8).
apoE3
Diameter (I)
**
Peak 1
Diameter (I)
**
Peak 2 Diameter (V)
**
WT 10.961.4 68 671 0 . 4 61.7
R145C 13.763.6 137667 11.363.1
K146E 10.661.4 58661 0 . 1 61.7
R136S 17.161.2 n/d* 16.962.1
Calculated particle diameters are given in nm. Errors indicate peak width. Peak 2
corresponds to ,1% of the total mass of the protein sample and indicates
higher order aggregates. Units are in nm. Values are means 6 SD from three
experiments.
*non-detected.
**I= diameter calculated based on the distribution of intensities of scattering,
V= diameter calculated after normalization of the scattering distribution based
on particle volume occupancy.
doi:10.1371/journal.pone.0027037.t005
Table 4. Parameters calculated from DMPC remodeling
experiments for apoE3 variants.
apoE3
t1/2 fast
(sec)
t1/2 slow
(sec) % plateau
WT 176692 10396143 17613
R145C 133641 1416±69* 2463
K146E 145662 12476303 1462
R136S 165685 1378±178** 1564
Data were fit to a two-state exponential decay model. Half-lives for each
component of the decay are shown. Values are means 6 SD from three
experiments.
*p=0.012, **p=0.004.
doi:10.1371/journal.pone.0027037.t004
Figure 8. Volume-normalized distribution of particle hydrody-
namic diameters in 0.1 mg/ml samples of WT apoE3 and
variants. Peak analysis parameters are shown in Table 5.
doi:10.1371/journal.pone.0027037.g008
Figure 9. Panel A, Location of amino-acid substitutions in the
apoE3 variants under study in the recently determined
structure of a monomeric variant of apoE3 (pdb code 2L7B).
Protein is shown in cartoon representation with the N-terminal domain
colored in blue, the C-terminal domain colored in red and the hinge-
domain colored in green (see reference [68]). Panel B, same as in panel
A, but with the C-terminal and N-terminal domain shown in surface
representation to demonstrate that positions 136, 145 and 146 are not
solvent exposed in this structure. Panel C, interactions between amino
acids R136, R145 and K146 and the C-terminal or N-terminal domain of
the protein. All three amino acids are stabilized by specific interactions
with either charged residues of the C-terminal domain (for K146 or
R136) or with hydrogen bonding within the N-terminal domain [68].
Images were prepared using PyMol 1.3 (www.pymol.org).
doi:10.1371/journal.pone.0027037.g009
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that are under intense scrutiny due to their role in the pathogenesis
of cardiovascular and Alzheimer’s disease [45,74].
The precise molecular mechanism that links specific apoE
mutations with dominant forms of type III HLP remains unclear.
In many cases the studied molecular properties of apoE variants
associated with the disease do not correlate well with disease
penetrance or severity indicating that other factors may also
contribute to the pathogenesis of the disease. For example, apoE2,
which is associated with a recessive form of type III HLP, binds to
the LDL receptor 50-fold weaker than apoE3 [22,75]. In contrast,
all apoE3 variants studied here demonstrate stronger LDL
receptor binding compared to wild-type apoE2 [28,30,34,35].
Still, these variants not only maintain their ability to predispose to
type III HLP, but also do so in a dominant fashion, unlike apoE2
[22,26,30,31,33,34,35]. These observations suggest that these
variants must carry additional properties that contribute to their
pathogenic potential.
In this study we hypothesized that type III HLP predisposing
mutations may lead to alterations in the structure and thermody-
namic stability of apoE3 since such alterations have previously
been linked with the pathogenic potential of the protein. We
further hypothesized that the common pathogenic potential of
these variants may be derived by similar thermonynamic or
structural consequences. Indeed, our findings point to specific
changes in the thermodynamic properties of the variants. These
changes however are distinct between the three variants suggesting
that they do not constitute a single unifying mechanism leading to
protein dysfunction and that further functional analysis will be
necessary to clarify their role in apoE3 function. It is possible
however, given the importance of structural plasticity of apoE3 to
its function, that the molecule’s thermodynamic stability is
optimized to provide sufficient stability in the lipid-free form but
at the same time sufficient lability to allow unfolding transitions
upon lipid interactions. In this context any deviation from this
optimized state, regardless if they are destabilizing or stabilizing
may signify altered dynamics between different apoE3 conforma-
tions in solution that are detrimental to apoE3 function.
In summary, in this study we analyzed the biophysical
properties of three apoE3 variants that predispose to the
development of type III HLP. We found statistically significant
differences in several parameters examined indicating that these
single-amino acid variations can affect the stability and confor-
mational distribution of apoE3 in solution. We were unable
however to discern a unifying pattern between the observed
thermodynamic alterations in each variant that could be used to
develop a single thermodynamics-based hypothesis regarding their
pathogenic potential. Although it is possible that the thermody-
namic alterations in each variant lead to common dysfunctions in
the structural plasticity of apoE3, the relatively small magnitude of
the perturbations makes it less likely that they constitute a primary
factor. Regardless, these alterations in the biophysical properties of
these variants should be taken into account in further functional
analysis aiming to clarify the link between apoE3 and the
development of type III HLP.
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